Compare Liberty Global Ltd Class C (LBTYK) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liberty Global Ltd Class C vs Novo Nordisk A/S — how do they compare? Liberty Global Ltd Class C trades at $8.52 (market cap $3.06B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 54× Liberty Global Ltd Class C's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Liberty Global Ltd Class C pays none. Which is the better fit depends on your goals — on Pluang, investors hold Liberty Global Ltd Class C for 21 Days and Novo Nordisk A/S for 116 Days on average.
| LBTYK | NVO | |
|---|---|---|
Market Cap | $3.06B | $165.31B |
Volume | 2,508,956 | 11,432,838 |
Sector | Media | Health |
52-Week High | $12.67 | $63.98 |
52-Week Low | $8.75 | $35.29 |
Typical Hold Time | 21 Days | 116 Days |
Enterprise Value | $9.72B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Liberty Global (LBTYK) trades at $8.52, down 4.48% amid bearish technical signals. The stock shows mixed fundamentals with strong gross margins of 67.17% but significant net losses. Recent earnings have been volatile, with Q1 2026 beating expectations but Q2 missing. The company is progressing with strategic initiatives including the Ziggo Group spin-off planned for 2027 and an AI partnership with Sierra.
Despite current losses, analyst consensus remains bullish with a $12.67 price target, suggesting 49% upside. Key risks include execution of the Ziggo listing and sustained profitability challenges. The cash position and asset monetization provide downside support, while the planned 2027 value-unlock event represents the primary growth catalyst.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
